ACRP CCRC Exam 2023 Prep Questions
Answers/ Verified.
What are expected or possible consequences of over-estimation of recruitment
potential? - -- The trial will overrun its projected timeline
- The recruitment period will be prolonged and more sites may be needed
- The study will not have sufficient data within the required timeframe and will be
stopped because of lack of budget
-What should be the first consideration when conducting a clinical trial? - -Subject
welfare
-When is the investigator allowed to deviate from the protocol? - -When there is an
immediate hazard to a patient.
-If the investigator wanted to deviate from the protocol for an immediate hazard to a
patient, according to ICH E6 guidelines who world they need to report the deviation and
rationale to, if appropriate? - -- The Sponsor
- IRB/IEC
- Regulatory Authorities
-Which conditions should be fulfilled when enrolling a subject into your trial? - --
Subject meets all inclusion criteria
- Subject has given written informed consent
-You've been delegated to handle the storage and inventory of IP. The study drug must
be stored below 25C/77F. On a summer Monday morning you discover that the
temperature recording machine in the storage room has failed so you doin't know what
the temperature has been over the weekend. You check the current temperature; it's
,24C/75F. What should you do? - -- Contact the Sponsor, explain what happened and ask
for instructions
- Set up a site staff meeting to conduct a root cause analysis
-A protocol amendment was issued for a trial. Your site received IRB approval for the
amendment and wants to implement the increase in PO dose for your trial subjects as
identified in the amendment trial subjects. As delegated consenting duties you must re-
consent trial subjects before being able to administer the adjusted dose. You decide to
only re-consent trial subjects who are still taking the IP and not from the subjects woh
already completed their drug intake period. Is this allowed according the E6 Guideline
for GCP? - -No, these subjects are still enrolled in the trial and therefore need to be
updated on any changes to the protocol.
-A trial subject informs you she no longer wants to participant in the trial. What should
your course of action be? - -You ask if the patient wishes to share the reason why she
wants to leave the trial. If not, you exclude the subject from the trial immediately.
-A patient cannot recall the name of the heart condition medication he took a few years
ago. This is important information for deciding whether the patient may be enrolled in a
clinical trial (IC/EC). What's your best course of action? - -You attempt to retrieve the
patients medical history by contacting previous caregivers and you wait for additional
information before enrollment.
-Who has ultimate trial responsibility for each subject? - -The principle investigator.
-A trial subject suffers from severe repeat headaches. Should this adverse event be
reported to the IRB? - -No
-What statements are true concerning an adverse drug reaction? - -- All noxious and
unintended responses to a medicinal product related to any dose should be considered
as an ADR
- An ADR suggests a relationship to trail medication
,- All ADRs must be documented
-What Adverse Events (AEs) are Serious Adverse Events (SAEs)? - -- Any AE that
results in death
- Any AE that results in inpatient hospitalization
- Any AE that is a congenital anomaly
-During a study visit a patient tells the investigator that she visited an emergency room
and received intensive treatment for allergic bronchospasm. Since the patient was in the
emergency room for only three hours, the investigator did not assess the event as
serious. Is this a correct assessment? - -No, this would be a medically important event
and should be considered serious
-What data points minimally need to be reported by the site when reporting an SAE, so
that the sponsor can process the event? - -Identification of event, product, and trial
subject
-During a visit with investigator, a subject reported feeling heart palpitations for a brief
period of time during the previous evening. The heart palpitations resolved without
reoccurrence. The investigator considered these symptoms to be unrelated to study
drug. The next day, the subject told a fellow student that he felt tired and was planning
on taking a nap. Later, the subject was found dead. A preliminary report from the
medical examiner indicated the subject died of pulmonary embolism. What should your
next course of action be? - -- Record these events in case report form
- Immediately notify sponsor about serious adverse events
-When asked by a regulatory body why they received SAE related information on
12/2013 from an incident that occurred in 5/2013, the sponsor explained the reason
being they received the trial related SAE information from the investigator in 12/2013.
Is the sponsor correct in only holding the investigator accountable for their late
reporting? - -No, the sponsor should support the conduct QC activities with the sites to
help them ensure timely SAE reporting.
, -A trial subject in a cardiology trial is admitted to hospital with heart attack. The
investigator considers this event possibly related to the study drug even though this is
not listed in the IB as a potential adverse reaction. What would the investigator report
this event to the sponsor as? - -An unexpected, serious adverse event
-A 22y/o male was entered into a clinical study for treatment of schizophrenia The
study drug was administered orally, BID. One week later, the subject visited the
investigator complaining of sever sore throat. The IB lists this as an occurrence reported
by 1% of subjects receiving drug. How should this severe throat be classified? - -- An
adverse event
- An adverse drug reaction
-In regards to AE and ADR reporting, what statements are true? - -- All ADRs are AEs
but not all AEs are ADRs
- Worsening in pre-existing medical conditions is an AE
-Preplanned hospitalization is usually not an SAE
-What determines the causality of an adverse event? - -The investigator
-Which term best describes the cyclical process that involves the Plan, Do, Check, Act
activities? - -Quality improvement
-Which term best describes an independent assessment of completed work to ensure it
will meet applicable quality standards? - -Quality assurance
-Which term best describes the activities done to ensure quality output? - -Quality
control
-Which term requires structure and a definition of acceptable standards of
performance? - -Quality planning
Answers/ Verified.
What are expected or possible consequences of over-estimation of recruitment
potential? - -- The trial will overrun its projected timeline
- The recruitment period will be prolonged and more sites may be needed
- The study will not have sufficient data within the required timeframe and will be
stopped because of lack of budget
-What should be the first consideration when conducting a clinical trial? - -Subject
welfare
-When is the investigator allowed to deviate from the protocol? - -When there is an
immediate hazard to a patient.
-If the investigator wanted to deviate from the protocol for an immediate hazard to a
patient, according to ICH E6 guidelines who world they need to report the deviation and
rationale to, if appropriate? - -- The Sponsor
- IRB/IEC
- Regulatory Authorities
-Which conditions should be fulfilled when enrolling a subject into your trial? - --
Subject meets all inclusion criteria
- Subject has given written informed consent
-You've been delegated to handle the storage and inventory of IP. The study drug must
be stored below 25C/77F. On a summer Monday morning you discover that the
temperature recording machine in the storage room has failed so you doin't know what
the temperature has been over the weekend. You check the current temperature; it's
,24C/75F. What should you do? - -- Contact the Sponsor, explain what happened and ask
for instructions
- Set up a site staff meeting to conduct a root cause analysis
-A protocol amendment was issued for a trial. Your site received IRB approval for the
amendment and wants to implement the increase in PO dose for your trial subjects as
identified in the amendment trial subjects. As delegated consenting duties you must re-
consent trial subjects before being able to administer the adjusted dose. You decide to
only re-consent trial subjects who are still taking the IP and not from the subjects woh
already completed their drug intake period. Is this allowed according the E6 Guideline
for GCP? - -No, these subjects are still enrolled in the trial and therefore need to be
updated on any changes to the protocol.
-A trial subject informs you she no longer wants to participant in the trial. What should
your course of action be? - -You ask if the patient wishes to share the reason why she
wants to leave the trial. If not, you exclude the subject from the trial immediately.
-A patient cannot recall the name of the heart condition medication he took a few years
ago. This is important information for deciding whether the patient may be enrolled in a
clinical trial (IC/EC). What's your best course of action? - -You attempt to retrieve the
patients medical history by contacting previous caregivers and you wait for additional
information before enrollment.
-Who has ultimate trial responsibility for each subject? - -The principle investigator.
-A trial subject suffers from severe repeat headaches. Should this adverse event be
reported to the IRB? - -No
-What statements are true concerning an adverse drug reaction? - -- All noxious and
unintended responses to a medicinal product related to any dose should be considered
as an ADR
- An ADR suggests a relationship to trail medication
,- All ADRs must be documented
-What Adverse Events (AEs) are Serious Adverse Events (SAEs)? - -- Any AE that
results in death
- Any AE that results in inpatient hospitalization
- Any AE that is a congenital anomaly
-During a study visit a patient tells the investigator that she visited an emergency room
and received intensive treatment for allergic bronchospasm. Since the patient was in the
emergency room for only three hours, the investigator did not assess the event as
serious. Is this a correct assessment? - -No, this would be a medically important event
and should be considered serious
-What data points minimally need to be reported by the site when reporting an SAE, so
that the sponsor can process the event? - -Identification of event, product, and trial
subject
-During a visit with investigator, a subject reported feeling heart palpitations for a brief
period of time during the previous evening. The heart palpitations resolved without
reoccurrence. The investigator considered these symptoms to be unrelated to study
drug. The next day, the subject told a fellow student that he felt tired and was planning
on taking a nap. Later, the subject was found dead. A preliminary report from the
medical examiner indicated the subject died of pulmonary embolism. What should your
next course of action be? - -- Record these events in case report form
- Immediately notify sponsor about serious adverse events
-When asked by a regulatory body why they received SAE related information on
12/2013 from an incident that occurred in 5/2013, the sponsor explained the reason
being they received the trial related SAE information from the investigator in 12/2013.
Is the sponsor correct in only holding the investigator accountable for their late
reporting? - -No, the sponsor should support the conduct QC activities with the sites to
help them ensure timely SAE reporting.
, -A trial subject in a cardiology trial is admitted to hospital with heart attack. The
investigator considers this event possibly related to the study drug even though this is
not listed in the IB as a potential adverse reaction. What would the investigator report
this event to the sponsor as? - -An unexpected, serious adverse event
-A 22y/o male was entered into a clinical study for treatment of schizophrenia The
study drug was administered orally, BID. One week later, the subject visited the
investigator complaining of sever sore throat. The IB lists this as an occurrence reported
by 1% of subjects receiving drug. How should this severe throat be classified? - -- An
adverse event
- An adverse drug reaction
-In regards to AE and ADR reporting, what statements are true? - -- All ADRs are AEs
but not all AEs are ADRs
- Worsening in pre-existing medical conditions is an AE
-Preplanned hospitalization is usually not an SAE
-What determines the causality of an adverse event? - -The investigator
-Which term best describes the cyclical process that involves the Plan, Do, Check, Act
activities? - -Quality improvement
-Which term best describes an independent assessment of completed work to ensure it
will meet applicable quality standards? - -Quality assurance
-Which term best describes the activities done to ensure quality output? - -Quality
control
-Which term requires structure and a definition of acceptable standards of
performance? - -Quality planning
